Immune globulin subcutaneous (human) 20: In primary immunodeficiency disorders

Drugs

Volumn 72, Issue 8, 2012, Pages 1087-1097

  McCormack, Paul L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Adis Drug Profiles; Agammaglobulinaemia; Immune globulin; Immunodeficiency disorders

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; PNEUMOCOCCUS VACCINE; PROLINE; TETANUS ANTIBODY;

ABDOMINAL DISCOMFORT; ACUTE SINUSITIS; AGAMMAGLOBULINEMIA; ARTICLE; BACKACHE; BRONCHITIS; CHRONIC LYMPHATIC LEUKEMIA; COMMON VARIABLE IMMUNODEFICIENCY; COMPARATIVE STUDY; COUGHING; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GOLD STANDARD; HAEMOPHILUS INFLUENZAE TYPE B; HEMOLYSIS; HUMAN; HUMORAL IMMUNE DEFICIENCY; HYPOTHERMIA; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE REACTION; META ANALYSIS; MYOSITIS; NAUSEA; OROPHARYNX PAIN; PATIENT SATISFACTION; PHASE 1 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; RHINOPHARYNGITIS; SEVERE COMBINED IMMUNODEFICIENCY; SINUSITIS; STREPTOCOCCUS PNEUMONIAE; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; VIRUS INACTIVATION; VOMITING; WISKOTT ALDRICH SYNDROME; X LINKED AGAMMAGLOBULINEMIA;

CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFUSIONS, SUBCUTANEOUS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

BACTERIA (MICROORGANISMS);

EID: 84861443275     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11209490-000000000-00000     Document Type: Article

References (24)

1. Merck & Co. The Merck manual online: overview of immunodeficiency disorders. 2008 Sep [online]. Available from URL:http://www.merckmanuals.com/ professional/immunology-allergic-disorders/immunodeficiency-disord ers/overview-of-immunodeficiency-disorders.html [Accessed 2012 May 6]
2. Jolles S, Sleasman JW. Subcutaneous immunoglobulin replacement therapy with Hizentra-, the first 20% SCIG preparation: a practical approach. Adv Ther 2011; 28 (7): 521-33
3. Jolles S, Bernatowska E, de Gracia J, et al. Efficacy and safety of Hizentra in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011; 141 (1): 90-102
4. Berger M. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Curr Opin Allergy Clin Immunol 2011; 11 (6): 532-8
5. Gardulf A, Nicolay U. Replacement IgG therapy and selftherapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol 2006 Dec; 6 (6): 434-42 (Pubitemid 44714156)
6. Berger M. L-proline-stabilized human IgG: Privigen 10% for intravenous use and Hizentra 20% for subcutaneous use. Immunother 2011; 3 (2): 163-76
7. Maeder W, Lieby P, Sebald A, et al. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals 2011; 39 (1): 43-9
8. European Medicines Agency. Hizentra (human normal immunoglobulin [SCIg]): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Informa tion/human/002127/WC500107057.pdf [Accessed 2012 May 4]
9. CSL Behring. Hizentra, immune globulin subcutaneous (human), 20% liquid: US prescribing information [online]. Available from URL: http://www.hizentra. com/docs/hi zentraPI.pdf [Accessed 2012 May 4]
10. Stucki M, Schäfer W, Hostettler T, et al. Pathogen safety of a new 20% liquid immunoglobulin product [abstract no. 331]. J Allergy Clin Immunol 2009; 123 (2 Suppl. 1): S89
11. Stucki M, Boschetti N, Schäfer W, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008 Jul; 36 (4): 239-47
12. Berger M. Incidence of infection is inversely related to steadystate (trough) serumIgGlevel in studies of subcutaneous IgG in PIDD. J Clin Immunol 2011; 31 (5): 924-6
13. Orange JS, Grossman WJ, Navickis RJ, et al. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010 Oct; 137 (1): 21-30
14. Wasserman RL, Melamed I, Nelson RP, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 2011; 50 (6): 405-14
15. Berger M, Rojavin M, Kiessling P, et al. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011; 139 (2): 133-41
16. Thépot S, MalphettesM, Gardeur A, et al. Immunoglobulin dosage and switch from intravenous to subcutaneous immunoglobulin replacement therapy in patients with primary hypogammaglobulinemia: decreasing dosage does not alter serum IgG levels. J Clin Immunol 2010; 30 (4): 602-6
17. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30 (5): 734-45
18. Nelson RP, Melamed I, Stein MR, et al. Safety, tolerability, and efficacy of Hizentra over an extended period for the treatment of primary immunodeficiency disease [abstract no. 314]. J Allergy Clin Immunol 2012; 129 (2 Suppl.): AB83.
19. Plus poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting; 2012 Mar 2-6; Orlando (FL)
20. Jones CA, Rojavin M, Baggish JS. Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety. J Pharm Health Serv Res 2012 Mar; 3 (1): 41-7
21. Conley ME, Notarangelo LD, Etzioni A, representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Diagnostic criteria for primary immunodeficiencies. Clin Immunol 1999 Dec; 93 (3): 190-7
22. Borte M, Pac M, Serban M, et al. Efficacy and safety of Hizentra, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol 2011; 31 (5): 752-61
23. Quevedo TG, Mannhardt-Laakmann W, Bernatowska E, et al. Health-related quality of life of patients with primary immunodeficiency switching from intravenous IgG to a new 20% subcutaneous IgG [abstract no. F39]. Clin Immunol 2010; 135 Suppl.: S87.
24. Plus poster presented at the 10th Annual Meeting of the Federation of Clinical Immunology Societies; 2010 Jun 24-27; Boston (MA)